Synonyms: | |
Status: | Phase 3 |
Entry Type: | Small molecule |
Molecule Category: | UNKNOWN |
UNII: | 5P60F84FBH |
InChI Key | YALNUENQHAQXEA-UHFFFAOYSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C24H27N3O4 |
Molecular Weight | 421.5 |
AlogP | 4.55 |
Hydrogen Bond Acceptor | 5.0 |
Hydrogen Bond Donor | 3.0 |
Number of Rotational Bond | 8.0 |
Polar Surface Area | 90.9 |
Molecular species | BASE |
Aromatic Rings | 3.0 |
Heavy Atoms | 31.0 |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class I
|
- | 133 | - | 2-2 | - | |
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIa
|
- | 512 | - | 1050-1050 | - | |
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | 44-312 | - | 4-4 | - | |
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IV
|
- | 287 | - | - | - | |
Unclassified protein
|
- | 136 | - | - | - |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Muscular Dystrophy, Duchenne | 3 | D020388 | ClinicalTrials |
Muscular Dystrophy, Duchenne | 3 | D020388 | ClinicalTrials |
Muscular Dystrophy, Duchenne | 3 | D020388 | ClinicalTrials |
Myeloproliferative Disorders | 2 | D009196 | ClinicalTrials |
Arthritis, Juvenile | 2 | D001171 | ClinicalTrials |
Multiple Myeloma | 2 | D009101 | ClinicalTrials |
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | D015451 | ClinicalTrials |
Polycythemia Vera | 1 | D011087 | ClinicalTrials |
Crohn Disease | 1 | D003424 | ClinicalTrials |
Hodgkin Disease | 1 | D006689 | ClinicalTrials |
Resources | Reference |
---|---|
CAS NUMBER | 497833-27-9 |
ChEBI | 94187 |
ChEMBL | CHEMBL1213492 |
DrugBank | DB12645 |
EPA CompTox | DTXSID70198049 |
FDA SRS | 5P60F84FBH |
Guide to Pharmacology | 7490 |
PDB | QCM |
PubChem | 9804992 |
SureChEMBL | SCHEMBL1555814 |
ZINC | ZINC000003820616 |